| 11.34 0.19 (1.7%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.23  |
1-year : | 21.6 |
| Resists | First : | 15.6 |
Second : | 18.5 |
| Pivot price | 12.24 |
|||
| Supports | First : | 10.93 |
Second : | 9.09 |
| MAs | MA(5) : | 11.39 |
MA(20) : | 12.88 |
| MA(100) : | 13.09  |
MA(250) : | 13.42 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 5 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 29.7 | Low : | 7.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADVM ] has closed above bottom band by 23.0%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.36 - 11.42 | 11.42 - 11.48 |
| Low: | 10.76 - 10.85 | 10.85 - 10.92 |
| Close: | 11.22 - 11.34 | 11.34 - 11.45 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Fri, 19 Apr 2024
Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) - Yahoo Finance
Tue, 16 Apr 2024
What's in Store for Adverum (ADVM) This Earnings Season? - Yahoo Movies UK
Thu, 04 Apr 2024
How Adverum (ADVM) Stock Stands Out in a Strong Industry - Yahoo Finance
Thu, 04 Apr 2024
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? - Yahoo Finance
Tue, 19 Mar 2024
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mon, 18 Mar 2024
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.172e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 543 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1812e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 437.9 % |
| Return on Equity (ttm) | -32.2 % |
| Qtrly Rev. Growth | 3.6e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -111.94 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -91 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 1.08 |
| Dividend | 0 |
| Forward Dividend | 889950 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|